(PNOC-005) A Phase 1 Study of Modified Measles Virus (MV-NIS) for the Treatment of Children and Young Adults with Recurrent Medulloblastoma or Recurrent Atypical Teratoid Rhabdoid Tumors (ATRT)
This study will look to determine the safety and recommended phase 2 dose of the modified measles virus (MV-NIS) in children and young adults with recurrent medulloblastoma or atypical teratoid rhabdoid tumor (ATRT).
- 12 months - 39 years old
- Disease: Medulloblastoma
For additional information about eligibility criteria, please contact the study coordinator Jennifer King:
- Drug: Modified Measles Virus
For additional information about study procedures, please contact the study coordinator Jennifer King:
Can be done from home
Keywordsatypical teratoid rhabdoid tumor (ATRT), recurrent medulloblastoma, pediatric brain tumor, Brain Tumors, Brain Tumor
Principal InvestigatorSridharan Gururangan, FRCP
Begin a new search for other research studies
Studies listed on this site have been approved by a UF Institutional Review Board (IRB), which works to ensure the welfare and rights of research participants as required by federal regulations. Study listings are provided by the UF Clinical and Translational Science Institute in collaboration with UF research teams and the UF IRBs.